April 14–17, 2019
Renaissance Washington DC Downtown Hotel

Research, Development And Strategic Partnering For The Global Vaccine Industry

@vaccinenation
terrapinn.com/vaccine-usa-sponsor
Great opportunity to Network, learn of new developments and trends of the industry and obtain Insights to the strategies companies are using to grow their business.

For the past 18 years, the World Vaccine Congress Washington congress has evolved and grown into the leading vaccines congress globally, in content, speakers, attendees and networking opportunities.

Back in 2015, we introduced a successful new format which allowed for whole-sector topics, giving an opportunity for people to find out more about their specific area of research and their job-function. By running parallel niche conferences over the 3 days, it increased the relevance of the whole event for everyone who attended.

The impact of this has been to increase the quality of the speaker line-up and those who sign up to attend, as the content truly moved forward, covering the important blue-sky keynotes whilst also providing personalised content for every attendee.

In 2019, we will be continuing this format with the pre-congress workshops and conferences in Cancer Immunotherapy, Immune Profiling, Respiratory Vaccines, Emerging & Re-emerging Diseases, Clinical Trials, Vaccine Partnerships, Bioprocess & Manufacture, Vaccines Safety, Logistics and Veterinary Vaccines. We will also be looking to expand into newer topic areas such as BioDefense, Big Data and Bioinformatics in a greater capacity, engaging more profiles from Army, DoD, non-profits and national representatives in healthcare than ever before.

Throughout these sessions you will learn how cutting-edge research efforts can be integrated with pharma, biotech, academia and government to produce more and better vaccines to the market.

With so much on show throughout these four days and unparalleled networking and learning opportunities, we’re confident that you will walk away from this year’s congress safe in the knowledge that your time has been well worth it.

We look forward to welcoming you there.
Confirmed Keynotes Include

**Scientific Advisory Board**

- **COL DEYDRE S. TEYHEN**
  DPT, PhD, OCS, Commander,
  Walter Reed Army Institute of Research (WRAIR)

- **DR GREGORY A. POLAND**
  Director of Mayo Vaccine Research Group
  Mayo Clinic

- **PROF STANLEY PLOTKIN**
  Emeritus Professor
  University of Pennsylvania
  School of Medicine

- **DR WALTER STRAUS**
  Associate Vice President,
  Therapeutic Area Head, Clinical Safety and Risk Management
  Merck Research Laboratories

- **DR JERALD SADOFF**
  Senior Advisor
  Janssen Infectious Diseases and Vaccines

- **DR HEIDI LARSON**
  Professor of Anthropology, Risk
  and Decision Science
  London School of Hygiene and Tropical Medicine

- **DR MICHAEL NALLY**
  President, Global Vaccines
  Merck

- **MARK FEINBERG**
  CEO
  IAVI

- **STEVE DAVIS**
  President and CEO
  PATH

- **DR KATHERINE J. LARSON**
  Senior Vice President and Head,
  Global Clinical Development and
  Chief Medical Officer
  Merck Research Laboratories

- **DR PAUL OFFIT**
  Chief Division of Infectious Diseases
  & Director of the Vaccine Education Center
  Children's Hospital of Philadelphia; Perelman School of Medicine at
  University of Pennsylvania

- **DR PETER HOTEZ**
  Dean of National School of Tropical Medicine
  Baylor College of Medicine

- **DR GEORGE SIBER**
  Exec Director, CEO of ClearPath
  Vaccines & Chair of Scientific
  Advisory Board, Genocea Biosciences

- **PROF MARK DAVIS**
  The Burt and Marion Avery
  Family Professor, Microbiology & Immunology
  Stanford University

- **PROF BALI PULENDRAN**
  Dpt of Pathology, Microbiology & Immunology
  Stanford University School of Medicine

- **DR BRUCE GELLIN**
  President of Global Immunization
  Sabin Vaccine Institute

- **DR ROY BAYNES**
  Senior Vice President and Head,
  Global Clinical Development and
  Chief Medical Officer
  Merck Research Laboratories

- **DR PAUL OFFIT**
  Chief Division of Infectious Diseases
  & Director of the Vaccine Education Center
  Children's Hospital of Philadelphia; Perelman School of Medicine at
  University of Pennsylvania

- **DR PETER HOTEZ**
  Dean of National School of Tropical Medicine
  Baylor College of Medicine

- **DR GEORGE SIBER**
  Exec Director, CEO of ClearPath
  Vaccines & Chair of Scientific
  Advisory Board, Genocea Biosciences

- **PROF MARK DAVIS**
  The Burt and Marion Avery
  Family Professor, Microbiology & Immunology
  Stanford University

- **PROF BALI PULENDRAN**
  Dpt of Pathology, Microbiology & Immunology
  Stanford University School of Medicine

- **DR BRUCE GELLIN**
  President of Global Immunization
  Sabin Vaccine Institute

- **DR ROY BAYNES**
  Senior Vice President and Head,
  Global Clinical Development and
  Chief Medical Officer
  Merck Research Laboratories

- **DR PAUL OFFIT**
  Chief Division of Infectious Diseases
  & Director of the Vaccine Education Center
  Children's Hospital of Philadelphia; Perelman School of Medicine at
  University of Pennsylvania

- **DR ROY BAYNES**
  Senior Vice President and Head,
  Global Clinical Development and
  Chief Medical Officer
  Merck Research Laboratories

- **DR PAUL OFFIT**
  Chief Division of Infectious Diseases
  & Director of the Vaccine Education Center
  Children's Hospital of Philadelphia; Perelman School of Medicine at
  University of Pennsylvania

- **DR PAUL OFFIT**
  Chief Division of Infectious Diseases
  & Director of the Vaccine Education Center
  Children's Hospital of Philadelphia; Perelman School of Medicine at
  University of Pennsylvania
300+ Confirmed speakers include:

Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic

Dr. John R. Mascola, Director of the Dale and Betty Bumpers Vaccine Research Institute, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health

Dr. Nicole Lurie, Strategic Advisor to CEO, CEPI

Dr. Julia Spencer, Associate Director, Global Vaccine Action Network, Partnerships, & Government Affairs, Merck

Dr. Vashee Moorthy, Team Leader, Vaccine Development, WHO

Dr. Cyril Gay, National Program Leader, ARS, USDA

Dr. Paul Offit, Chief Division of Infectious Diseases & Immunology, Children’s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania

Dr. Stanley Plotkin, Emeritus Professor, University of Pennsylvania School of Medicine

Dr. Jeff Ulmer, Head, Preclinical US R&D, GSK

Dr. Arturo Casadevall, Chairman of Molecular Microbiology and Immunology, John Hopkins Bloomberg School of Public Health

Dr. David Mantus, Chief Development Officer, Aramis Biosciences GmbH

Dr. Galit Alter, Associate Professor in Medicine, Principle Investigator, Harvard Medical School

Dr. Mark Esser, Senior Director, Vaccines and Infectious Diseases - Translational Medicine, Moderna Therapeutics

Dr. Mike Watson, SVP, Vaccine Partnerships & Health Impact Project - Moderna Therapeutics

Dr. Darrell J. Irvine, Professor of Materials Science & Engineering and Biological Engineering, MIT

Dr. Ofir Levy, Staff Physician & Principal Investigator, Director, Advanced Vaccines Program

Dr. Derek O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Barney Graham, Deputy Director of Vaccines Research Center, National Institute of Allergy and Infectious Diseases

Dr. Jerome Kim, Director, General International Vaccines Institute (IVI)

Dr. Ke Liu, Chief, Oncology Branch, NCI, NCI-CTEP, FDA

Dr. Arnaud Didierlaurent, Senior Director-Head of Adjuvant platform, GSK Vaccines

Dr. Carl R. Alving, Emeritus Senior Scientist, Former Chief, Laboratory of Adjuvant Immunology Research, NIAID, National Institutes of Health, U.S. Military HIV Research Program. Walter Reed Army Institute of Research

Dr. Timothy Cooke, Board Director, Novavax, Therapeutics, Administrative Representative US National Vaccine Advisory Committee

Dr. Joseph A. Faktorov, PhD, Program Manager, OARPA

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Angela Shen, Professor of Veterinary Medicine, University of Pennsylvania School of Veterinary Medicine

Dr. Burnett B. Jackson, Professor of Medicine, Perelman School of Medicine, University of Pennsylvania

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Gerald Pies, Professor of Medicine (Microbiology and Immunology), Harvard Medical School

Dr. Roy Baynes, SVP and Head, Global Clinical Development, Janssen

Dr. Douglas McNeil, CMO, Novavax Vaccines Incorporated

Dr. Michael Kalos, Immunology and Translational Medicine, Janssen

Dr. Hani Pajar, Technical Development and Manufacturing Moderna Therapeutics

Dr. Pramod Srivastava, Professor Immunology and Medicine, Director of Cancer Center, University of Medicine and Science Institute

Dr. Cameron J. Thomas, Professor of Medicine, University of Virginia School of Medicine

Dr. Bryan Sive, Professor, Department of Immunology, Imperial College London

Dr. Robert A. Landis, Professor, Department of Pathology, University of Pennsylvania School of Medicine

Dr. Jennifer A. Prowell, Professor, Department of Biological Sciences, University of Delaware

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen

Dr. Bette T. Khoros, President, Global Development, and Global Medical Affairs, Sanofi Pasteur

Dr. Daniel O’Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines

Dr. Angela Shen, Former Senior Science Policy Advisor, U.S. Department of Health and Human Services

Dr. Andrew Skibo, Head of Global Biologics Operations and Global Engineering, AfraZemica/Medimmune

Dr. Dan Panesar, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Cindy Aronstein, Director, Division of Therapeutics, Drugs for Food Animals, CIRM for Veterinary Medicine, FDA

Dr. Annalisa Anderson, Chief Scientific Officer, Janssen Vaccines and the Hospital Business Unit, Janssen
New vaccine technology is changing the whole industry

Find ways to improve development of universal influenza, RSV, MERS and TB vaccines.

Optimize early formulation through to clinical manufacturing, by embracing new techniques and technologies.

From novel immunotherapy trends, cancer vaccines, oncolytic viruses to engineered T-cell therapies, join us to better understand the latest developments in the fast-evolving cancer landscape.

Discuss how profiling of the immune system using high throughput technologies can aid therapeutic design and treatment strategies in infectious and noninfectious diseases including cancer.

Hear from exciting new vaccine biotechs presenting on their pipeline as well as case studies and on how best to form public-private partnerships.

Assess how to improve your clinical trial performance, from developing novel immunological assays to creating clinical efficacy.

Understand the opportunities for your business in reacting to global threats like Zika, malaria, dengue and Ebola.

From livestock to companion, gain crucial insights into the emerging infections and new technologies changing the landscape.

Understand challenges in supply chain visibility from mitigating shortages to barcoding and serialization. Find out the latest improvements in cold chain technology, overcoming shipment challenges, capacity planning and the importance of economics for vaccine supply.

Get updates in the latest studies in risk assessment and communication of safety, understand vaccine safety infrastructure and surveillance systems as well as emerging innovations and case studies in vaccine safety science and pharmacovigilance.

---

**Agenda Overview**

**DAY 1**
- **APR 14**
  - PRE-CONGRESS WORKSHOPS
  - KEYNOTE PRESENTATIONS

**DAY 2**
- **APR 16**
  - IMMUNE PROFILING
  - CANCER & IMMUNOTHERAPY
  - RESPIRATORY & INFLUENZA
  - EMERGING & RE-EMERGING
  - CLINICAL TRIALS
  - VACCINE SAFETY
  - BIOPROCESSING & MANUFACTURING
  - SUPPLY & LOGISTICS
  - PARTNERSHIPS
  - VETERINARY

**DAY 3**
- **APR 17**
  - IMMUNE PROFILING
  - CANCER & IMMUNOTHERAPY
  - RESPIRATORY & INFLUENZA
  - EMERGING & RE-EMERGING
  - CLINICAL TRIALS
  - VACCINE SAFETY
  - BIOPROCESSING & MANUFACTURING
  - SUPPLY & LOGISTICS
  - PARTNERSHIPS
  - VETERINARY

**OFF-SITE 12TH VIE AWARDS**
**Workshop A: Vaccine Technology**

**Half Day Workshop**

*Emerging Tools – Paradigm shift in vaccine technologies*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title and Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-12:30</td>
<td>Development and testing of a human IgG1 monoclonal antibody to the broadly conserved microbial surface polysaccharide, PNAG.</td>
</tr>
<tr>
<td>12:30-14:00</td>
<td>RSV and bacterial (Sa and Pa) prophylactic monoclonals in development.</td>
</tr>
<tr>
<td>14:00-16:00</td>
<td>Anti-fungal immunotherapy - Cryptococcus Neoformans vaccine.</td>
</tr>
<tr>
<td>16:00-18:00</td>
<td>HIV adaptive immunity.</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Scientific rationale &amp; landscape of antibodies in preclinical and clinical development for infectious diseases.</td>
</tr>
</tbody>
</table>

**Workshop B: Passive Immunity for Infectious Diseases**

*10:00-5:30* | Antiviral monoclonals for infectious disease prevention and therapy. |

**Workshop C: Market Access**

*10:00-5:30* | Market access & regulatory challenges in vaccines. |

**Workshop D: Biodefence**

*10:00-5:30* | The role of vaccines in preventing outbreaks, through natural causes or biothreats. |
(10:00-5:30) Trials and tribulations of integrating adjuvants into your vaccine. What's the value of current and new adjuvants?

**Value of current adjuvants & research gaps**

- Dr Arnaud Didierlaurent, Senior Director-Head of Adjuvant platform, GSK Vaccines
- Dr Carl R. Alving, Emeritus Senior Scientist, Former Chief, Laboratory of Adjuvant & Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research
- Dr Ofer Levy, Director, Precision Vaccines Program, Boston Children's Hospital & Professor, Harvard Medical School
- Dr Amit Khandhar, GSK Vaccines Global Head of Discovery Support
- Dr Derek O'Hagan, Harvard Medical, Boston Children's Hospital & Professor
- Dr Ofer Levy, Director, Precision Vaccines Program, Boston Children's Hospital & Professor, Harvard Medical School
- Dr Bob Seder, Chief, Cellular Immunology Section, NIH

(10:00-12:30) The influence of the microbiome in vaccine response

**Workshop Leader:** Mollie Roth, Executive Director, The Microbiome Coalition

- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics
- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics
- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics
- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics
- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics
- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics
- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics

**The role of the microbiome in modulating the inflammatory response**

- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics

**When prevention is possible**

- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics

**Rational selection of bacteria cocktails**

- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics

**Delivering the right intervention to the right patient/population**

- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics

**Workshop Leader:** Mollie Roth, Executive Director, The Microbiome Coalition

(10:30-12:30) The role of the microbiome in modulating the inflammatory response

**When prevention is possible**

- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics

**Rational selection of bacteria cocktails**

- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics

**Delivering the right intervention to the right patient/population**

- Dr Mathew Hene, Executive VP, Microbiome R&D, Seres Therapeutics

**Workshop Leader:** Mollie Roth, Executive Director, The Microbiome Coalition

(1:30-5:30) HPV

**Explanations for the high potency of HPV prophylactic vaccines - Could we move from 3 to 1 dose regimens?**

- Dr John Schiller, Deputy Chief, Laboratory of Cellular Oncology, NIH Distinguished Investigator, Head, Neoplastic Disease Section, National Cancer Institute, NIH

**An Immunotherapeutic approach for HPV associated dysplasia**

- Dr Prakash Bhuyan, VP Clinical Development, Inovio

**Clinical progress of alternative therapeutic HPV vaccines**

- Dr Prakash Bhuyan, VP Clinical Development, Inovio

**HPV Discussion & Q&A with Audience**

- Dr Prakash Bhuyan, VP Clinical Development, Inovio

**Updates in early clinical development efforts to develop vaccine against Epstein Barr Virus**

- Dr Corey Casper, CMO, IDRI

**Rational design of a prophylactic Epstein-Barr Virus vaccine targeting infection of B cells and epithelial cells**

- Dr Jeffrey Cohen, Chief, Laboratory of Infectious Diseases, NIAID, NIH

**Progress of therapeutic vaccines against EBV associated cancers**

- Dr Graham Taylor, Senior Lecturer Tumor Immunology, Institute of Immunology and Immunotherapy, University of Birmingham

**EBV Discussion & Q&A with Audience**

- All EBV Speakers

**Workshop Leaders:**

- Workshop Leaders:

**Dr Basav Ghosh, Senior Director, Manufacturing Sciences and Technology, Pfizer**

**Dr Bo Arve, Executive Director, BioPharmaceutical Sciences, Pfizer**

**An analytical perspective**

- Senior representative, Pfizer

**A regulatory/Process perspective**

- Dr Willie Vann, Chief, Laboratory of Bacterial Polysaccharides, FDA

Clinical perspective on traditional vaccines

Differences from customized vaccines in orphan drug and ATMPs

Discussion with all speakers
Plenary Congress Day 1
Monday April 15, 2019

MORNING PLENARIES: RENAISSANCE BALLROOM

8:30 Chair’s opening remarks
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic

8:45 Plenary keynote insights: Strengthening the effectiveness of national, state & local efforts to improve the uptake of HPV vaccination
ADM Brett P. Giroir, M.D., Assistant Secretary for Health, U.S. Department of Health and Human Services (HHS)

8:55 Plenary keynote insights: What direction will vaccines take to ensure safety and mass immunization? Vaccine research and development in the public sector
Dr John R. Mascola, Director of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH

9:05 How can we be better prepared for disease X?
Dr Nicole Lurie, Strategic Advisor to CEO, CEPI
Dr Theresa Tam, Chief of Public Health Affairs Officer of Canada
Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, & Government Affairs, Merck
Col Deborah Whites, Former Commander, Walter Reed Army Institute of Research & Chief of Staff, Medical Research Materiel Command
Dr W. Ripley Ballou, Vice President and Head, Slasui Center for Vaccines Research, GSK Vaccines, Rockville MD

9:45 Networking coffee break

10:45 INTERACTIVE ROUNDTABLES
Choosing the right platform to look back and explore a range of topical issues that can be discussed with other thought leaders at a more interactive basis - 40 min per roundtable
To book a roundtable contact Wing yen Cheung@therrapinn.com

When limited patient resources meet unlimited immunotherapy combinations– the strategies to develop clinical IO agents in platform studies
Dr Jun Tang, Senior Representative, PPD

Changing landscape of real-world evidence and its impact on clinical research - uncovering lab & clinical adverse events
Walter Reed Army Institute of Research (WRAIR)

Developing more effective vaccines for emerging re-emerging pandemic threats
Dr James F. Cummings, MD, President, ICON Government and Public Health Solutions - title TBC

Overcoming obstacles to improve cold chain management of biologics

The use of ePRO solutions and endpoints in vaccine studies
Senior Representative, PPD - title TBC

Seasonal vaccine studies: Critical success factors
Cynthia Dukes, VP, Scientific and Clinical Services and Head of Vaccine Center of Excellence, ICON Clinical Research - title TBC

Artificial intelligence - adopting cognitive computing across the vaccine landscape

Challenges for development of GMO vaccines
Marc Hoffman, Chief Medical Officer & Arno von Hassel, Director Scientific Affairs, Calverton

Safety evaluation of vaccines: from now to tomorrow, new approaches and technologies?
Dr Nathalie Garcon, CSO & CEO, Bioaster

Oncology - applying informatics to find the best treatment option for each patient

Development of novel predictive algorithms for patient selection

Brexit, GMP and GMOs: Bruno Spelder, Head Clinical Regulatory Affairs, Consultancy & Adrian Wildfire, Project Director Infectious Diseases & Human Challenge Unit, SGS Life Sciences - title TBC

Best practices for a Successful CRO/Pharma partnership for vaccine clinical studies
Lynelle Burton, Director of Project Delivery - Vaccines, PBA Health Sciences - title TBC

Networking Lunch (Exhibition Hall)

1:10

2:10 POSTER Presentations & Pancakes

2:30 Networking coffee break

4:30 Networking coffee break

5:00 INTERACTIVE ROUNDTABLES
The continuing instrumental role of NGOs: Making the impossible, achievable

Dr Mark Feinberg, CEO & President, IAVI

Steve Davis, President and CEO, PATH

Robin Nandy, Principal Advisor, Chief of Immunizations, UNICEF

Dr David Robinson, Deputy Director, Vaccine Development and Surveillance, Bill & Melinda Gates Foundation

Dr Jerome Kim, Director General, IVI

5:30 The resurgence of immuno-oncology - Can they hold their promise?
Dr Richard Gaynor, President of Research and Development, Neon Therapeutics

Dr Roy Baynes, Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

Dr Stefano Masotti, Chargé de mission, World Organization for Animal Health (OIE)

One Health veterinary pharmacology strategy update
Sarena Lin, Executive Vice President, USA & Global Strategy, Elanco Animal Health

Dr Mahesh Kumar, Senior Vice President, Global Biologics Research, Zoetis

Dr Allison Flynn, Lead, North America Public Policy, Merck Animal Health

Dr Nigel Swift, Global Head of Vaccine Research & Development, Boehringer Ingelheim Animal Health

Operational framework for strengthening human & animal public health systems at their interface
Dr Lisa Conti, One Health Initiative Deputy Commissioner and Chief Science Officer, Florida Department of Agriculture and Consumer Service

Dr Michael Ryan, Deputy Director, WHO Emergencies Programme

Dr Jonathan Epstein, Vice President, Science and Outreach, EcoHealth Alliance

Dr Lisa Conti, One Health Initiative Deputy Commissioner and Chief Science Officer, Florida Department of Agriculture and Consumer Service

Fire chat: The future of the vaccine business from the executives
Paula Anunziata, Vice President & Therapeutic Area Head for Vaccines, Merck
Dr Annalessa Anderson, Chief Scientific Officer, Bacterial Vaccines and the Hospital Business Unit, Pfizer
Rajeev Venkayya, President, Global Vaccine Business Unit, Teleda
Dr Emmanuel Hanon, SVP, Head, R&D, GSK Vaccines

Johan Van Hoof, M.D., Global Therapeutic Area Head IDV, Vaccines Managing Director, Jansen Vaccines and Prevention B.V.

Dr Denilo Casimias, Vice President & Head, External R&D and Vaccine Platforms, Sanofi Pasteur

5:30 Networking coffee break

6:40 Chair’s Closing Remarks and Close of Congress Day 1

6:50 Post Awards Networking Drinks Reception (off-site)

7:30 Gala Dinner & 12th Annual ViE Awards Ceremony
Day 2 & 3: 10 co-conferences

<table>
<thead>
<tr>
<th>Conference</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune Profiling Conference</td>
<td>17 - 18</td>
</tr>
<tr>
<td>Cancer &amp; Immunotherapy Conference</td>
<td>19 - 20</td>
</tr>
<tr>
<td>Influenza &amp; Respiratory Conference</td>
<td>21 - 22</td>
</tr>
<tr>
<td>Emerging &amp; Re-Emerging Diseases Conference</td>
<td>23 - 24</td>
</tr>
<tr>
<td>Clinical Development &amp; Trials Conference</td>
<td>25 - 26</td>
</tr>
<tr>
<td>Vaccine Bioprocessing &amp; Manufacturing Conference</td>
<td>27 - 28</td>
</tr>
<tr>
<td>Partnerships Conference</td>
<td>29 - 30</td>
</tr>
<tr>
<td>Veterinary Vaccines Conference</td>
<td>31 - 32</td>
</tr>
<tr>
<td>Vaccine Safety Conference</td>
<td>33 - 34</td>
</tr>
<tr>
<td>Supply &amp; Logistics Conference</td>
<td>35</td>
</tr>
</tbody>
</table>

---

**Plenary Congress Day 3**

**Wednesday April 17, 2019**

---

**AFTERNOON PLENARY OF CONGRESS : RENAISSANCE BALLROOM**

**1:30**
**Chair’s opening remarks**
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic

**1:40**
**New lessons from old controversies**
Dr Paul Offit, Chief Division of Infectious Diseases & Director of the Vaccine Education Center, Children’s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania
Dr Stanley Plotkin, Eminent Professor, University of Pennsylvania School of Medicine
Dr Sarah Kobrin, Branch Chief, Health Systems and Interventions Research, NCI, NIH
Dr Bruce Y. Lee, MD MBA, Assoc. Prof of Int Health, Johns Hopkins Bloomberg School of Public Health

**2:55**
**A framework for a comprehensive maternal immunization platform**
Dr Saad Omer, Professor Global Health, Epidemiology and Pediatrics, Emory Vaccine Center, Emory University, Schools of Public Health & Medicine

**3:25**
**What is the status of the development pipeline for infectious disease vaccines in the US? Trends and implications for the future**
Dr Timothy Cooke, Biotechnology Industry Representative, US National Vaccine Advisory Committee
Dr Angela Shen, ScD, MPH, CAPT (ret), US Public Health Service Drexel University Dornsife School of Public Health

**4:00**
**Chair Closing Remarks and End of Congress**
Immune Profiling Conference, Day 2
Tuesday April 16, 2019

9:00 Chair’s opening remarks

KEYNOTES

9:10 Using systems immunology to understand vaccine-specific immunity
Dr. Stacey L. Wooden, Scientific Advisor, The Human Vaccines Project

9:20 Precision vaccines: Bringing precision medicine to vaccinology
Dr. Ofer Levy, Director, Precision Vaccines Program, Boston Children’s Hospital & Professor, Harvard Medical School

9:40 Explainable artificial intelligence (XAI) to gain insights into vaccine action
Dr. Richard Schuewermann, Director, J. Craig Venter Institute

10:40 Networking Lunch & Poster Session

IMMUNE PROFILING FOR INFECTIOUS DISEASES

11:40 Innate immune profiling for dengue infection & vaccination
Dr. Ana Fernandez-Sesma, Chair, Human Immunology Project Consortium & Professor, Icahn School of Medicine, Mount Sinai

12:20 Divergent immune responses to West Nile virus
Dr. Ruth Montgomery, Associate Professor of Medicine, Yale University School of Medicine

12:50 Immune responses to malaria infection and immunisation
Dr. Ken Stuart, Professor, Seattle Children’s Research Institute - Center for Global Infectious Disease Research

1:10 Networking Lunch & Poster Session

BIG DATA

3:40 Analysis of the antibody repertoire elicited by viral infection and vaccination to aid the development of more efficient vaccines
Dr. George Georgiou, Professor: Cellular and Biomolecular Engineering, The University of Texas

4:10 Networking Coffee Break

4:40 Systems-level profiling of influenza vaccination responses
Dr. Steven Kleinste, Associate Professor of Pathology, Yale University School of Medicine

5:10 Unlocking the power of the genome using state of the art bulk genetic sequencing and bioinformatics technologies

5:40 Case Study: Using single cell analysis to gain insight into how CD4 cytotoxic T cells arise in humans

6:10 Chair’s Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Immune Profiling Conference, Day 3
Wednesday April 17, 2019

9:00 Chair’s opening remarks

PRECISION CANCER TREATMENT

9:10 Targeting specific oncogenic pathways to restore the immune response against cancers
Professor Dean W. Felsher, Director, Translational Research and Applied Medicine, Oncology Research, Stanford University School of Medicine

9:20 Designing "nanosimmunotherapies" to modify the tumor microenvironment and potentiate robust systemic antitumor immune responses
Dr. Rohan Fernandes, Assistant Professor, Medicine, The George Washington University

9:40 The use of circulating free tumor DNA (ctDNA) for tumor characterization and patient treatment guidance

10:40 Networking Coffee Break

11:30 Biomarker strategies for patient selection
Dr. J-Ming Wang, Director, Translational Oncology, Pfizer
Dr. Robert Loberg, Director, Executive Director & Head of Clinical Biomarkers & Diagnostics, Amgen
Dr. Razvan Cristescu, Senior Principal Scientist, Merck

12:30 Networking Lunch & Poster Session

9:00 Chair’s opening remarks

10:40 Networking Coffee Break

11:30 Biomarker strategies for patient selection
Dr. J-Ming Wang, Director, Translational Oncology, Pfizer
Dr. Robert Loberg, Director, Executive Director & Head of Clinical Biomarkers & Diagnostics, Amgen
Dr. Razvan Cristescu, Senior Principal Scientist, Merck

12:30 Networking Lunch & Poster Session
**Cancer & Immunotherapy Conference, Day 2**

**Tuesday April 16, 2019**

### NOVEL IMMUNOTHERAPY TRENDS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution</th>
<th>Additional Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Chair’s opening remarks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10</td>
<td>How can we take the next step in cancer immunotherapy?</td>
<td>Dr Daniel Chen, CMO, IGM Bioscience; Former Vice President and Global Head of Cancer Immunotherapy Development, Genentech</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:40</td>
<td>Could radiotherapy lead to an in-situ breast cancer vaccine?</td>
<td>Dr Silvia Formanti, Chairman of the Department of Radiation Oncology, Weill-Cornell; Associate Director, Meyer Cancer Center; Radiation Oncologist-Chief, New York Presbyterian Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:10</td>
<td>Novel approaches to neoantigen identification lead to first ever genomics-driven personalized medicine clinical trial of ovarian cancer</td>
<td>Dr Pramed Srivastava, Professor, Immunology Division, Carole and Ray Neag Comprehensive Cancer Center, UConn Health</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CANCER VACCINES

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution</th>
<th>Additional Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:55</td>
<td>Virus-like particles for effective antigen delivery in therapeutic vaccines</td>
<td>Dr David Anderson, CSO, VBI Vaccines Inc</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td>Overview of Neon’s approach to the development of personalized cancer immunotherapies</td>
<td>Dr Maril van Bommel, Group Leader, T-cell Immunology, Neon Therapeutics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:25</td>
<td>Updates in the early clinical development of mRNA-based personalized cancer vaccines</td>
<td>Dr Harri Pujar, Head of Technical Development, Moderna Therapeutics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:40</td>
<td>DCVax® Personalized Immune Therapies for Cancer</td>
<td>Linda Powers, CEO, NW Bio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:10</td>
<td>Networking Lunch &amp; Poster Session</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ONCOLYTIC VIRUSES

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution</th>
<th>Additional Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:20</td>
<td>Oncolytic virus strategies</td>
<td>Dr Samuel Ruben, Thomas A. Pappas Professor of Neurosciences, Department of Neurosurgery (Microbiology &amp; Immunology), Massachusetts General Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td>Late stage clinical development of adenovirus-based immunotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:10</td>
<td>Networking coffee break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:40</td>
<td>Vaccinia virus-based immunotherapy for the treatment of solid tumors</td>
<td>Dr Steven Thorne, CSO, Western Oncology</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CHECKPOINTS, TARGETED DRUGS AND COMBINATIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution</th>
<th>Additional Notes</th>
</tr>
</thead>
</table>

---

**Cancer & Immunotherapy Conference, Day 3**

**Wednesday April 17, 2019**

### ENGINEERED CANCER IMMUNOTHERAPY: T CELLS TO BSPECIFICS, AND BEYOND

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution</th>
<th>Additional Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Chair’s opening remarks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:10</td>
<td>TCR Therapies targeting solid tumors</td>
<td>Dr Karen Chang, Vice President, Medical Clinical Development, Adaptimmune</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:40</td>
<td>Anti CD20/CD3 T-cell-dependent bispecific antibodies for hematologic malignancies</td>
<td>Dr Wayne Chu, Associate Group Medical Director, Product Development, Genentech</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td>BCMA CAR-T Therapies for multiple myeloma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:40</td>
<td>Networking Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Panel: Navigating the engineered cell therapy landscape - prospects and challenges</td>
<td>Dr Michael Kalos, Vice President, Immunology and Cell Therapies, Janssen; Dr Aiman Shalabi, Vice President R&amp;D, Cell and Gene Therapies, GSK; Dr Ke Liu, Chief Oncology Branch, FDA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Networking Lunch &amp; Poster Session</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Additional panellists TBC*
### Influenza and Respiratory Vaccines, Day 2

**Tuesday April 16, 2019**

**5:55**
- The reveal: Introduction to a new RSV vaccine
  - Dr Tod Merkel, Professor of Laboratory for Respiratory and Special Pathogens, Division, CBER, FDA

**6:10**
- Chair's Closing Remarks and Close of Congress Day 2

**6:15**
- Off-site Networking Drinks, follow the congress team

---

**RESPIRATORY INFECTIONS STRATEGY & CONTROL**

**9:10**
- Identifying adjuvants that stimulate a protective immune response in Pertussis
  - Dr Tim Hirst, Chairman & CEO, GPN Vaccines Pty Ltd

**9:40**
- A new broad-spectrum vaccine against Streptococcus pneumoniae
  - Dr Sean Tucker, CSO, Vaxart, Inc.

**9:55**
- MIMIX Flu, is a broadly protective, shelf-stable, self-administered influenza vaccine
  - Michael Schnader, Co-Founder and CEO, Vaxess Technologies, Inc.

**10:10**
- Broad cross-protection and heterologous challenge

**10:30**
- Influenza vaccines immunological assessment
  - Prof Emanuele Montomoli, Professor at the Public Health University of Siena & CSO, VisMederi

**10:40**
- Networking coffee break

---

### Influenza and Respiratory Vaccines, Day 3

**Wednesday April 17, 2019**

**9:10**
- Universal flu: are we any closer to finding the “holy grail”? The Grand Challenge
  - Dr James Crowe, Director, Vanderbilt Vaccine Center

**9:40**
- Universal flu targets
  - Dr Barney S. Graham, MD, Deputy Director, VRC, NIAID, NIH

**10:10**
- What we’ve learnt 100 years on for respiratory trials
  - Senior representative, PPD

**10:40**
- Networking coffee break

**11:30**
- COPD panel: The interplay of virus, bacterial pathogens and exacerbation, an opportunity for vaccines?
  - Dr Sanjay Sethi, Professor and Chief, Pulmonary, Critical Care and Sleep Medicine, Assistant Vice President for Health Sciences, University of Buffalo

**11:40**
- Ph3 efficacy results a VLP influenza vaccine
  - Senior representative, Medicago

**12:40**
- Ph2 oral vaccine for protection against influenza challenge in humans
  - Dr Sean Tucker, CSO, Vaxart, Inc.

**12:55**
- Ph2 NasoVAX report, a replication-deficient adenovirus vector technology intranasally delivered
  - Dr Scot Roberts, CSO, Altimmune

**2:40**
- Utilizing human challenge studies to accelerate the development of respiratory vaccines
  - Senior representative, hVIVO

**3:40**
- Structural vaccinology - RSV
  - Dr Peter Kwong, Structural Biology Section, Chief, Structural Bioinformatics Core, VRC, NIAID, NIH

**4:10**
- Networking coffee break

**4:40**
- Ph3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization
  - Dr Gregory M. Glenn, MD, President, Research and Development, Novavax

**5:00**
- GSK’s RSV vaccine pipeline update
  - Ilse Dieussaert, Director and Head of Maternal Immunization Vaccine Development, GSK Vaccines

**5:10**
- Ongoing development of a novel vaccine for Respiratory Syncytial Virus
  - Dr Christopher Heery, Chief Medical Off, Bavarian Nordic

---
Tuesday April 16 2019

A Plug-and-Play technology platform to expedite the production of vaccines for biodefense and emerging infectious diseases

How to achieve executional success in emerging/re-emerging disease studies with real world examples – The success formula

John Barry, Chief Operations Officer, Pharm-Olam International

5:40

Chair’s Closing Remarks and Close of Congress Day 2

6:10

Off-site Networking Drinks, follow the congress team

6:15

Tuesday April 16 2019

EBOLA & FLAVIVIRUS UPDATE

Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, & Government Affairs, Merck

2:55

Zika vaccine update

Dr Beth-Ann Coller, Executive Director, Global Clinical Development, Merck

3:40

Executing multi-international trials and research for infectious diseases at WRAIR

Col Nelson L. Michael, M.D., Ph.D., Former Deputy Commander; Zika Program Co-Lead and Directory of HIV Research, Colonel, Medical Corps, U.S. Army, Henry Jackson Foundation in support of the Walter Reed Army Institute of Research

4:40

Emerging and Re-emerging Diseases, Day 2

Chair’s opening remarks

9:00

Emerging and Re-emerging Diseases, Day 3

Chair’s opening remarks

9:00

Tuesday April 16 2019

Chair’s opening remarks

9:00

GLOBAL HEALTH PREPAREDNESS STRATEGY AND PLATFORM TECHNOLOGIES

Dr Wolfgang Bender, MD, CMO, Valneva

12:40

A single-dose live-attenuated Zika vaccine

Dr Pei-Yong Shi, I.H. Kempner Professor of Human Genetic, University of Texas Medical Branch at Galveston

12:55

ExpreS2 – An insect cell-based vaccine production system suitable for difficult-to-express proteins

Dr Max Soegaard, Director Process Development, ExpreS2ion Biotechnologies – Title to be confirmed

1:10

INTERVENTION TRIALS FOR AEDES-TRANSMITTED DISEASES

Dr Thomas Lingelbach, CEO, Valneva

2:40

Developing a novel vaccine for the prevention of Lyme disease: Development status and next steps

Thomas Lingelbach, CEO, Valneva

3:10

Dengue on trial

Moderator: Dr Duane J Gubler, ScD, FAAAS, FIDSA, FASTMH, Emeritus Professor, Programme in Emerging Infectious Diseases, Duke-NUS Medical School

Update on the TV003/TV005 vaccine trials Phase I through Phase III

Dr Anna Durbin, Professor, Johns Hopkins Bloomberg School of Public Health

Takeda’s PhIII dengue vaccine candidate

12:30

Networking Lunch & Poster Session

1:10

ELIMINATING GLOBAL INFECTIOUS DISEASES

What the gates MRI are doing: TB, malaria, enteric

Dr Walter A. Orenstein, MD, Professor and Associate Director, Emory Vaccine Center

10:40

Use of oral cholera vaccine as a key component to eliminate epidemic cholera as a public health threat

Dr Carl W. Dieffenbach, Director of the Division of AIDS (DAIDS), NIAID

11:40

Developing a single-shot vaccine against Chikungunya: VLA 1553 Phase 1 initial results and next steps

Dr Wolfgang Bender, MD, CMO, Valneva

12:00

Applying knowledge from HIV to develop a Lassa vaccine

GAS vaccine development

Dr Jerome Kim, Director General, IVI

12:25

A single-shot live-attenuated Zika vaccine

Dr Max Soegaard, Director Process Development, ExpreS2ion Biotechnologies – Title to be confirmed

12:40

Express52 - An insect cell-based vaccine production system suitable for difficult-to-express proteins

Dr Max Soegaard, Director Process Development, ExpreS2ion Biotechnologies – Title to be confirmed

1:10

Networking Lunch & Poster Session

1:10
Tuesday April 16, 2019

IMPROVING CLINICAL EFFICACY

9:00 Chair’s opening remarks

9:10 HIV vaccines in Clinical Trials
- Dr Dan Barouch, Professor of Medicine, Harvard Medical School
- Dr Larry Corey, President and Director Emeritus, Fred Hutchinson Cancer Research Center

10:10 Seasonal influenza vaccine efficacy studies: Lessons learned from 3 global studies
- Cynthia Dukes, VP, Scientific and Clinical Services and Head of Vaccine Center of Excellence, ICON Clinical Research

10:40 Networking Coffee Break

11:40 HIV vaccines in Clinical Trials
- Dr Dan Barouch, Professor of Medicine, Harvard Medical School
- Dr Larry Corey, President and Director Emeritus, Fred Hutchinson Cancer Research Center

12:10 Conceptualizing issues around routes of inoculation vs immunological response
- Adrian Wildfire, Project Director - Infectious Diseases & Human Viral Challenge Unit, SGS Life Sciences

12:40 Comparison of Zika virus neutralization assay platforms: PRNT and RVP
- Brent Seaton, Science Manager, Q² Solutions

12:55 NanoQuil - a novel next-generation saponin adjuvant
- Dr Laurent Duroux, Scientist R&D, Brenntag Biosector

1:10 Networking Lunch & Poster Session

2:40 Overcoming clinical efficacy issues in developing new adjuvants

2:45 Networking Coffee Break

3:10 Identifying immune responses that predict disease protection

3:40 Correlates of protection in vaccine clinical development
- Jakub Simon, Director Clinical Research, Vaccines Merck & Co.

4:10 Networking Coffee Break

A DEEP DIVE IN HUMAN CHALLENGE STUDIES

4:40 Frontiers in controlled human malaria infection (CHMI): accelerating malaria vaccine development, use in HIV+ populations, and empowering malaria research in Africa
- Thomas Richie, Chief Medical Officer, Sanaria Inc.

5:10 How do we move forward in Zika vaccine development using the Human Challenge Model
- Dr Anna Durbin, Professor, Johns Hopkins Bloomberg School of Public Health

5:40 The "how's" of Human Challenge Model studies (CHIMS)
- Dr John Treanor, Professor of Medicine, University of Rochester
- Philip Krause, Deputy Director, FDA

6:10 Chair’s Closing Remarks and Close of Congress Day 2

Wednesday April 17, 2019

NOSOCOMIAL INFECTIONS & VACCINES FOR UNCONVENTIONAL DISEASES

9:00 Chair’s opening remarks

9:10 Could vaccination be the potential strategy against antibiotic resistance?

10:10 Are bacterial vaccines harder to develop?
- Annaliesa Anderson, VP and Chief Scientific Officer, Bacterial Vaccines, Pfizer

10:40 Networking Coffee Break

11:30 Broad spectrum pneumococcal conjugate vaccines in development
- Grant Pickering, Chief Executive Officer, Sutrovax

12:00 Glycoconjugate vaccine development for Klebsiella pneumoniae and Pseudomonas aeruginosa infections prevention
- Raphael Simon, Assistant Professor of Medicine, University of Maryland School of Medicine

12:30 Networking Lunch & Poster Session

2:40 Overcoming challenges in seasonal vaccine studies
- Senior representative, Syneos Health

2:45 Networking Coffee Break

3:10 Identifying immune responses that predict disease protection

3:40 Correlates of protection in vaccine clinical development
- Jakub Simon, Director Clinical Research, Vaccines Merck & Co.

4:10 Networking Coffee Break

3:10 Overcoming challenges in seasonal vaccine studies
- Senior representative, Syneos Health

4:40 Frontiers in controlled human malaria infection (CHMI): accelerating malaria vaccine development, use in HIV+ populations, and empowering malaria research in Africa
- Thomas Richie, Chief Medical Officer, Sanaria Inc.

5:10 How do we move forward in Zika vaccine development using the Human Challenge Model
- Dr Anna Durbin, Professor, Johns Hopkins Bloomberg School of Public Health

5:40 The "how’s" of Human Challenge Model studies (CHIMS)
- Dr John Treanor, Professor of Medicine, University of Rochester
- Philip Krause, Deputy Director, FDA

6:10 Chair’s Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

terrapinn.com/vaccine-usa-sponsor
Tuesday April 16, 2019

Chair’s opening remarks

VACCINE BIOPROCESSING TRENDS AND CHALLENGES

New Models: How are smaller product development organizations (biotechs/non-profit/academics) manufacturing vaccine products for early and exploratory PoC clinical trials? Are larger Biopharma adapting as well?

Speakers from:
- Non-profit: Dr Antu Dey, Senior Director, R&D, IAVI
- Industry/big pharma: TBC
- Academic/small biotech: TBC

Process & Product Development using new technologies & Regulatory challenges in entering clinic

10:40 Networking Coffee Break

DESIGNING VACCINES FOR GLOBAL HEALTH

Latest advancements in production process intensification to support demand for affordable vaccines

Dr Christopher Yallop, Chief Operations and Scientific Officer, Batavia Biosciences

Bridging the global health gap - Viral and bacterial vaccine development

Senior representative, Intravacc

Outsource manufacturing of your vaccine candidate: The do’s and don’ts

Senior representative, Wacker Biotech

Establishing manufacturing capabilities in developing markets

Senior representative, Sartorius-Stedim

11:10 Networking Lunch & Poster Session

VACCINE PRODUCTION FOR OUTBREAKS

Vaccine self-sufficiency and responding to pandemic outbreaks from small to large scale

Dr Peter H. Khoury, President & CEO, Ology Bioservices, Inc

Accelerating vaccine production as part of a rapid response system

Senior representative, GE Healthcare

Initiating international multi-stakeholder collaborations from public health, government and manufacturers

12:40 Networking Lunch & Poster Session

ALTERNATIVE DELIVERY PLATFORMS

Alternative delivery system technology showcase

Dr Erin Spiegel, Director of Scientific Affairs, PharmaJet, Inc

Clinical milestone in skin vaccination: Combining the P.L.E.A.S.E.® epidermal system with the dry-patch technology boosts immunogenicity in an adjuvant-free setting

Reinhard Braun, CEO, Pantec Biosolutions AG, Liechtenstein, Pantec

Alternative delivery system technology showcase

Dr Iva Spiegel, Director of Scientific Affairs, PharmaJet, Inc

The Delivery Board: Reviewing presentations and their effectiveness

Darin Zehrung, Program Advisor and Portfolio Leader of the Vaccine and Pharmaceutical Delivery Technologies, PATH

Additional board members TBC*

Chair’s Closing Remarks and Close of Congress Day 2

6:10 Networking Lunch & Poster Session

Wednesday April 17, 2019

Chair’s opening remarks

MANUFACTURING PLATFORMS

Manufacturing technology showcase: Stockpiling heat stable oral vaccines to combat emerging disease

Manufacturing technology showcase: Development of EcoCRM®, a new GMP CRM197 carrier protein

Dr Andrew Lees, Scientific Director, Fina BioSolutions

Manufacturing technology showcase: Practical solutions enabling rapid and sustainable production

Senior representation, Paragon

Manufacturing technology showcase: Scalable in vitro manufacturing of tailored vaccines

Alexander Koglin, Founder, NIXBio

10:40 Networking Coffee Break

Incorporating AI and big data into more effective vaccine manufacturing

11:30 Manufacturing technology showcase

Expectations and CMC strategies for infectious disease monoclonal antibodies

Dr KC Cheng, Senior Director, Analytical and Formulation Development, Vaccine Production Program, VRC, NIH

12:30 Networking Lunch & Poster Session

Vaccine Bioprocessing & Manufacturing Conference, Day 3

Vaccine Bioprocessing & Manufacturing Conference, Day 2

Alternative delivery system technology showcase

Microprojection array patch clinical study with influenza vaccine: Demonstration of efficacy, dose reduction, and high temperature stability

Thomas Lake, Senior Vice President, Vaccine Development Alliances, Vaxxas

The Delivery Board: Reviewing presentations and their effectiveness

Darin Zehrung, Program Advisor and Portfolio Leader of the Vaccine and Pharmaceutical Delivery Technologies, PATH

Additional board members TBC*

6:10 Chair’s Closing Remarks and Close of Congress Day 2

6:15 Off-site Networking Drinks, follow the congress team

Off-site Networking Drinks, follow the congress team
Overcoming manufacturing challenges in the veterinary vaccine industry

Where is the future in veterinary vaccine delivery?

Orally administered vaccines for poultry

Aqua Culture: Overcoming routes of administration challenges

Chair’s Closing Remarks and Close of Congress Day 2

Off-site Networking Drinks, follow the congress team

SCIENTIFIC ADVANCEMENTS IN ANIMAL HEALTH

Structural vaccinology and its potential impact on the next generation of veterinary vaccines

Bridging the adjuvants gap between vet & human

Networking Lunch & Poster Session

Animal viruses engineered as human vaccines against infections of animals transmissible to humans

Incorporating precision vaccines into swine health: The use of RNA tech Sequivity to develop custom vaccines targeting specific diseases in individual herds

Networking Lunch & Poster Session

Precision breeding for animal health: How gene editing will improve our livestock systems

Monoclonal antibodies for companion animal allergic skin diseases

Deceptive imprinting: A cosmopolitan host immune evading strategy of animal health pathogens

Networking Lunch & Poster Session

VACCINE DELIVERY & MANUFACTURE

Where is the future in veterinary vaccine delivery?

Orally administered vaccines for poultry

Aqua Culture: Overcoming routes of administration challenges

Chair’s Closing Remarks and Close of Congress Day 2

Off-site Networking Drinks, follow the congress team

ALTERNATIVES TO ANTIBIOTICS

Overcoming the challenges of bacterial vaccine design

Developing vaccines against bacterial pathogens in animal species and humans using a salmonella vaccine vector platform

Regulatory pathways to enable the licensing of alternatives to antibiotics

Networking Coffee Break

EMERGING & RE-EMERGING DISEASES

Establishing a One Health approach to combat emerging zoonotic & transboundary diseases

PREDICT project: Detection and discovery of zoonotic diseases at the wildlife-human interface

New tools to combat Respiratory PRRS

African Swine Fever – Still no vaccine, updates on how the animal health industry is targeting this disease?
Vaccine Partnerships Conference Day 2

Tuesday April 16, 2019

**Antimicrobial Resistance**

9:00
Chair’s Opening Remarks
Barry Eisenstein, Chair, Scientific Advisory Board, Carb-X

9:20
FireChat 1 - Bacterial Vaccine
Gary Eldridge, President and CEO, Sequoia Sciences

9:40
FireChat 2 - Reducing bacterial adherence may lessen morbidity and mortality caused by urinary tract infections
Dr Mike Levine, GSK

10:00
FireChat 3 - A combination, live attenuated, oral vaccine against Shigella and ETEC infections
Frank Maliszewski, CMO, EvelVax

10:40
Networking Coffee Break

**Big Pharmaceuticals Investing in Novel Platforms & Viral Vectors Resistance**

11:00
Reserved

11:20
FireChat 4 - DNA vaccine

11:40
FireChat 5 - Developing infectious disease vaccine using mRNA technologies for pharmacologically optimized protein coding RNA
Dr Annette Vogel, Head of Infectious Disease Vaccines, BioNTech

12:20
FireChat 6 - Developing novel cancer immunotherapies based on optimized, antigen-encoding and complexed mRNA molecules
Dr Benjamin Petech, Head of Vaccines, CureVac GmbH

12:40
FireChat 7 - The Role of early stage companies in the pursuit of a universal flu vaccine
Dr Joseph Eiden, Senior Medical Consultant, Flugen

1:10
Networking Coffee Break

**Successful Partnering Case Studies**

2:40
Strategies for Effective Partnerships with the US Government, NGOs, International Collaborators and Beyond.
David Noll, PhD, Senior Vice President, Tiber Creek Partners

3:50
The “Big Four” explore how they partner and what they are looking for in a partner
Dr Philippe Denison, Director, External R&D and Innovation, GSK

Christopher Tan, Director, Business Development & Licensing, Search & Evaluation, Infectious Diseases and Vaccines, Merck

Julia LL, Director, Global Lead External Science and Innovation, Pfizer

Dr Roman Cziesa, Global Head of External Research and Development, Sanofi Pasteur

Successful case study 1: Sanofi - Translate Bio collaboration to develop mRNA vaccines for multiple infectious diseases
Mark Patterson, Senior director and Head of External R&D, Sanofi

Frank DellRosa, SVP, Head of Research and Development, TranslateBio

4:10
Networking Lunch & Poster Session

---

Vaccine Partnerships Conference Day 3

Wednesday April 17, 2019

**Vaccinology Alphabet Soup: What These Organizations Do and What Vaccine Programs They Are Supporting**

9:00
NIH - Emerging Diseases, Vaccination and Immunization Strategy
Dr Cristina Cassetti, Virology Branch Chief, NIH

UNICEF - An update on vaccine procurement and global immunization strategy
Robin Nandy, Principal Adviser, Chief of Immunizations, UNICEF

EDCTP - Public-Private partnership between Europe and sub-Saharan Africa to accelerate the development of vaccines
Michael Makanga, Executive Director, European and Developing Countries Clinical Trials Partnership

NVPO - Priorities and how to improve vaccination system in the US, Adult Immunization, Vaccine Safety
Dr Melinda Wharton, Acting Director, NVPO

NVAC - National Vaccine Plan Strategy, Topics affecting Vaccine Enterprise
Dr Kimberly Thompson, Chair, NVAC

ACIP - Recommendations on use of vaccines to public

10:25
Neglected Diseases

11:30
How to expand vaccine development of neglected diseases to a truly international level
Representatives from: Europe, Africa, Mexico, Saudi, South America

Dr David Diemert, Representative, University of Maryland

Remko Van Leewen, Director Acquisitions, Gilead Sciences

Mashal Almutairi, Director of Global Solutions, Biogen

Rodrigo Correa-Oliveira, Project Director, Global Health Initiatives, Merck

12:30
Networking Lunch & Poster Session
Vaccine Safety Conference Day 2

Tuesday April 16, 2019

Chair's opening remarks

VACCINE COMMUNICATION - RISK ASSESSMENT AND COMMUNICATION OF SAFETY

9:10
Perceived and real risks of vaccines in pregnancy
Dr Heidi Larson, Professor of Anthropology, Risk and Decision Science LSHTM

9:40
Strategies to enhance vaccine acceptance in future generations
Dr Ed Lewis, Research Professor, Millen Institute for Public Health, Georgetown University
Dr Barbara Paul, Associate Director, Vaccine and Treatment Evaluation Unit, Kansas City; Associate Professor of Pediatrics, Children's Mercy Hospital, Kansas City

10:40
Networking Coffee Break

UNDERSTANDING THE SYSTEM

11:40
Overview of US vaccine safety infrastructure
Dr Daniel Salmon, Director, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health

12:10
Panel: Does industry believe in the value of Sentinel?
Dr Walter Straus, Associate Vice President, Therapeutic Area Head, Clinical Safety and Risk Management, Merck Research Laboratories
Dr Jens-Ulrich Stegmann, Vice President Head Clinical Safety and Pharmacovigilance, GSK

1:10
Networking Lunch & Poster Session

EMERGING SCIENCE IN VACCINE SAFETY

2:40
Development of new statistical methods for evaluating the comparative safety of different childhood vaccine schedules

3:10
Keeping up with changing regulatory demands in vaccine safety monitoring
Reserved

3:40
Updates from the Uppsala Monitoring Centre
Dr Rebecca Chandler, Research Physician, Uppsala Monitoring Center

4:10
Networking Coffee Break

4:40
Challenges in post-licensure safety studies using real world data. Example: Hepatitis b vaccine
Dr Steven Jacobsen, Senior Director of Research, Kaiser Permanente Southern California

5:10
Joint presentation: Emerging innovations in vaccine safety science, perspectives from academia and industry
Dr Miriam Sturkenboom, Professor, Department of Global Health, Julius Center, University Medical Center Utrecht
Dr Jens-Ulrich Stegmann, Vice President Head Clinical Safety and Pharmacovigilance, GSK

5:40
How big data can lead to safer drugs and vaccines
Dr Jennifer Nelson, Director of Biostatistics & Senior Investigator, Biostatistics Unit, Kaiser Permanente Washington Health Research Institute

5:10
Chair’s Closing Remarks and Close of Congress Day 2

6:15
Off site Networking Drinks, follow the congress team

Vaccine Safety Conference Day 3

Wednesday April 17, 2019

Chair's opening remarks

VACCINE SAFETY CASE STUDIES

9:10
Safety monitoring of vaccines targeting special populations (e.g. elderly, maternal): Current challenges and approaches
Fernanda Torres de Silva, Senior Director, Head of Safety Evaluation & Risk Management, R&D Center GSK Vaccines

9:40
Joint presentation: Challenges in trial design, implementation and safety assessment of an Ebola vaccine under clinical development
Dr Wendy Carr, STRIVE Ebola Vaccine Trial Regulatory Oversight Lead, CDC

10:40
Networking Coffee Break

11:10
Considerations for safety assessment of a new class of mRNA vaccines

12:00
Adversomics: a glimpse into the future
Dr Inna Ovsyannikova, Professor of Medicine, Mayo Clinic

12:30
Networking Lunch & Poster Session
Vaccine Supply & Logistics Conference Day 2

Tuesday April 16, 2019

9:00 Chair's opening remarks

ECONOMICS OF SUPPLY

9:10 Getting to market faster – economics of new product supply
Charles Heffernan, Former Supply Chain Transformation and Technology Innovation Lead, GSK & Member of BioPhorum Operations Group, BPOG

9:40 How can economics help inform decisions that drive the supply and demand for vaccines
Patrick Wedlock, Research Associate, Bloomberg School of Public Health, Johns Hopkins University

10:10 How to limit impact of supply disruptions on country vaccination programs

10:40 Networking Coffee Break

SUPPLY CHAIN VISIBILITY

11:40 Barcoding and serialization – lessons learned from implementation

12:10 Supply chain surveillance – advantage of real-time surveillance of sub suppliers throughout the supply chain

12:40 Ensuring stability in the packaging and distribution of biological products including vaccines
Rebecca Gentile, Associate Director, Global Vaccine & Biological Stability, Merck

1:10 Networking Lunch & Poster Session

LOGISTICS COORDINATION AND COLD CHAIN TECHNOLOGY

2:40 Working with multiple partners to contain an outbreak – Ebola outbreak case study
Katherine DeLand, Chief of Staff, Ebola Response, World Health Organisation

3:10 Consequences for supply chain management of new vaccine introduction

3:40 Overcoming key supply chain challenges for vaccine shipments - *Session title TBC
Paddy Hanlon, Vice President, Global Key Accounts, Marken

4:10 Networking coffee break

4:40 Advances in cold chain technology with integrated tracking software
Reserved

5:10 Panel: Capital Investment Decisions: How to strategically plan to ensure sufficient capacity
Dr James Wassil, Business Unit Lead, Vaccines, Global Health & Value, Pfizer
Andrew Skibo, EVP, Head of Global Biologics and Global Engineering, AstraZeneca
Dr Norbert Klein, VP Manufacturing Science and Technology, GSK
Alec McCurdy, Director, Global Vaccine Marketing Operations, Merck

6:10 Networking Lunch & Poster Session

6:15 Off-site Networking Drinks, follow the congress team
Attendee Profiles

WHO ATTENDS
CEOs, CSOs, Directors and Heads from:
- Big Pharma
- Biotechs
- National and International Government
- Non-Profit Organizations
- Academics And Research Institutions

Microbiome
- Head, Microbiome Discovery Research
- Group Leader Microbiomics
- Senior Investigator, Immunology
- Immuno-Biology Lead

Emerging tools
- Structural biology
- Systems Biology
- Computational Biology
- Vaccinomics or “omics”

Passive immunity
- Monoclonal antibody (mAbs)
- Infectious diseases

Biotherapeutics
- Vaccines in Anthrax, Smallpox or Ebola
- Bacteriophages
- Biodefense
- Countermeasures
- Rapid response

Market Access
- Market shaping
- International Policy & Access
- Global Pricing
- Development and Commercialization
- Epidemiology and health economics
- Life cycle management

WHO SHOULD SPONSOR?
This is a great opportunity for specialists in oncology from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Vaccine delivery technology

WHO ATTENDS
CEOs, CSOs, Directors and Heads from:
- WHO ATTENDS
- Logistics / Cold Chain
- Biotechs
- Platform Technology Providers

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines for animal health from:
- CMOs
- OEMs / Equipment Manufacturers
- Platform Technology Providers
- Biotechs
- Big Pharma

WHO ATTENDS
CEOs, CSOs, Directors and Heads from:
- WHO ATTENDS
- Vaccine Production and Supply
- Head of Quality Assurance (QA)
- Head of Assurance
- Head of Supply Operations
- Head of Logistics

WHO SHOULD SPONSOR?
This is a great opportunity for specialists in influenza and respiratory vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Logistics / Cold Chain

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccine delivery technology from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Regulatory Affairs

WHO ATTENDS
CEOs, CSOs, Directors and Heads from:
- WHO ATTENDS
- Vaccine delivery technology
- Head of Regulatory Affairs
- Head of R&D

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- CMOs
- OEMs / Equipment Manufacturers
- Platform Technology Providers
- Biotechs
- Big Pharma

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO ATTENDS
CEOs, CSOs, Directors and Heads from:
- WHO ATTENDS
- Vaccine delivery technology
- Head of Regulatory Affairs
- Head of R&D

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO ATTENDS
CEOs, CSOs, Directors and Heads from:
- WHO ATTENDS
- Vaccine delivery technology
- Head of Regulatory Affairs
- Head of R&D

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs

WHO SHOULD SPONSOR?
This is a key opportunity for specialists in vaccines from:
- Platform Technology Providers
- Biotechs
- Big Pharma
- Contractors on Legal affairs
- Contractors on Regulatory Affairs
1200+ Attendees From

**40+ ATTENDING COUNTRIES**

<table>
<thead>
<tr>
<th>AMERICAS</th>
<th>APAC</th>
<th>EMEA</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>Australia</td>
<td>Austria</td>
</tr>
<tr>
<td>Canada</td>
<td>China</td>
<td>Belgium</td>
</tr>
<tr>
<td>Argentina</td>
<td>India</td>
<td>Germany</td>
</tr>
<tr>
<td>Brazil</td>
<td>Japan</td>
<td>Denmark</td>
</tr>
<tr>
<td>Mexico</td>
<td>New Zealand</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>Chile</td>
<td>Republic Of Korea</td>
<td>Democratic</td>
</tr>
<tr>
<td>Peru</td>
<td>Singapore</td>
<td>Republic Of The</td>
</tr>
<tr>
<td>Columbia</td>
<td>Taiwan</td>
<td>Congo</td>
</tr>
<tr>
<td>Panama</td>
<td>Malaysia</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Italy</td>
</tr>
</tbody>
</table>

Want to educate and engage with vaccine end users genuinely interested in your services?

**TAKE THIS OPPORTUNITY TO HOST A ROUNDTABLE DISCUSSION ON YOUR CHOSEN TOPIC**
Why Sponsor

SPEAKING OPPORTUNITIES
If your company is interested in delivering a thought leadership, education or case study presentation at the event in the conference agenda, we have limited slots as per the following sponsorship packages.

EXCLUSIVE KEYNOTE TITLE
Exclusive to one company only, you will have the opportunity to present in the KEYNOTE plenary alongside a handful of the very top vaccine industry thought leaders, and in an audience of over 800 decision makers. No other company at the event will have the same chance to position itself in the same way in your area of expertise, so offering unparalleled visibility to demonstrate your offering as the leader in your field.

PLATINUM
Presenting to a more targeted vaccine audience in your specific area of expertise, this is an exclusive opportunity to be the session lead sponsor and one of the first speakers of the relevant conference track.

GOLD
If you are looking for a platform to demonstrate and educate the leading vaccine decision makers of the full range of your services and capabilities, we have a few limited presentation opportunities within each targeted conference track to present in.

SILVER
Either chair one of the conference track sessions relevant for your business or join one of the limited relevant panel discussions.

ROUNDTABLE
Opportunity to host/moderate one of the Roundtables discussions on a topic of your choice.

NETWORKING OPPORTUNITIES
A core focus of the event outside the conference sessions is for all attendees to be able to network and develop lasting relationships with each other to drive their businesses. We have several tools for this as follows:

PRIVATE SPONSOR MEETINGS
If you have access to this exclusive service your networking manager will meet you with your pre-confirmed meeting agenda for the 3 days, where these will take place at your reserved table within the Sponsor Networking Table area.

DRINKS NETWORKING RECEPTION
Following the close of Days 1 & 2 conference sessions there will be complimentary networking drinks reception for all attendees to enjoy, and continue the discussions of the day in an informal and relaxed atmosphere.

EXTENDED NETWORKING LUNCHES AND BREAKS
Extra time has been allocated for networking during the breaks to ensure maximum opportunities for developing business relationships.

JUJAMA PARTNERING TOOL
Please use this powerful platform and app to continue to set up meetings on-site with other delegates, as well as after the event where it will stay live to communicate. Create and maintain a public profile, request meetings with other members, manage a personalised schedule of event sessions and meetings, send private in-app messages to other members and much more.

For meetings already set up these will take place within the exhibition area at your allocated table that was confirmed to you for the meeting. Please turn up at the specified time for your meeting and keep within the time limit so that the next set of meetings can run on time as scheduled. If for any reason you need to change the time or contact the delegate you are meeting, this can be done in real time on the app.

Sponsorship Packages

Premium sponsorship packages are for innovative companies serious about making their mark. Sponsorship packages are tailored to meet your specific marketing goals. The grid below is a guide to what you can expect at each level.

<table>
<thead>
<tr>
<th>Benefits</th>
<th>Title</th>
<th>Platinum</th>
<th>Gold</th>
<th>Silver</th>
<th>Bronze</th>
<th>Exhibitor</th>
<th>Table Top</th>
<th>Biotech Showcase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusive Keynote Title</td>
<td>Keynote Plenary</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaking Slot in relevant track</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Host a Roundtable</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speak on a Panel Session</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair Half Day</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pre-arranged on site meetings</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exhibition Booth</td>
<td>20ft x 16ft</td>
<td>20ft x 8ft</td>
<td>10ft x 8ft</td>
<td>10ft x 8ft</td>
<td>10ft x 8ft</td>
<td>10ft x 8ft</td>
<td>6ft x 6ft</td>
</tr>
<tr>
<td></td>
<td>Sponsor Networking Drinks Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Event Lanyards</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Event bags</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Delegate passes</td>
<td>8</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

OTHER SPONSORSHIP OPTIONS

<table>
<thead>
<tr>
<th>WiFi</th>
<th>Stationary</th>
<th>Coffee Stations</th>
<th>Workshops</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charging Stations</td>
<td>Networking Zone</td>
<td>On-line Networking Portal</td>
<td>Site Tours</td>
</tr>
</tbody>
</table>

To exhibit, sponsor or speak at this event call Marc Rhys-Evans on +44 (0)20 7827 5945 or email marc.rhys-evans@terrapinn.com
The Exhibition

To exhibit, sponsor or speak at next year’s event call Marc Rhys-Evans on +44 (0)20 7827 5945 or email marc.rhys-evans@terrapinn.com
12th Annual ViE Awards

These awards have been created to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry. 10 categories will be hotly contested in 2019.

Awards Ceremony and Gala Dinner

Taking place during the evening of April 15th, 2019, the ViE Awards will be recognizing vaccine practitioners and stakeholders across the global industry. The awards ceremony and gala dinner provides guests with the perfect opportunity to network with clients and prospects, and is an ideal end to the congress day. The ViE Awards 2018 were a huge success, with over 450 stakeholders in attendance, and the 2019 awards ceremony is already building to be even bigger and better so be sure to nominate and vote for your organization or peers.

Nominations and voting dates:

- **November 26th, 2018** – NOMINATING STAGE
  1st Round of Company nominations begin in each Category (industry can nominate any relevant and worthy company in each Awards category, compiled for 1st stage of voting from January 12th)
- **January 11th, 2019** – VOTING STAGE
  Company nominations close and Voting begins on all the organisations put forward in each Awards category with a DEADLINE of March 1st (from this voting the list will be narrowed down on March 1st to the shortlist of 6 organisations in each category)
- **March 1st, 2019** – VOTING CLOSES
  6 Shortlisted Organisations in each category are determined based on the votes so far, and notified within the following few days for completion of the Awards Submission Document to be reviewed by the Scientific Advisory Board. This will also be listed on the website by the 8th March
- **March 9th, 2018** – SUBMISSION DEADLINE
  Award submissions document deadline for shortlisted organisations (to be provided to Scientific Advisory Board in tandem with the votes)
- **April 15th, 2019** – AWARDS CEREMONY & DINNER
  Winners are announced at the 12th ViE Awards Ceremony & Gala Dinner

<table>
<thead>
<tr>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best Clinical Trial Site or Network</td>
</tr>
<tr>
<td>Best Contract Research Organization</td>
</tr>
<tr>
<td>Best Production/Process Development</td>
</tr>
<tr>
<td>Best Contract Manufacturing Organization</td>
</tr>
<tr>
<td>Best New Vaccine Technology/platform</td>
</tr>
<tr>
<td>Best Academic Research Team</td>
</tr>
<tr>
<td>Best Veterinary Vaccine</td>
</tr>
<tr>
<td>Best Therapeutic Vaccine</td>
</tr>
<tr>
<td>Best Prophylactic Vaccine</td>
</tr>
<tr>
<td>Best Pharma Company</td>
</tr>
</tbody>
</table>

Current 2019 Sponsors & Exhibitors

<table>
<thead>
<tr>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLATINUM SPONSORS</td>
</tr>
<tr>
<td>GOLD SPONSORS</td>
</tr>
<tr>
<td>SILVER SPONSORS</td>
</tr>
<tr>
<td>BRONZE SPONSORS</td>
</tr>
<tr>
<td>SHOWCASE SPONSORS</td>
</tr>
<tr>
<td>EXHIBITORS</td>
</tr>
</tbody>
</table>